Immix Biopharma Inc
IMMX
Company Profile
Business description
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Contact
11400 West Olympic Boulevard
Suite 200
Los AngelesCA90064
USAT: +1 310 651-8041
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
21
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks
Impact of ANZ’s huge fine
Working to prevent repeated failures could also improve competitiveness.
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.50 | 5.00 | -0.05% |
| CAC 40 | 7,818.22 | 78.71 | -1.00% |
| DAX 40 | 23,329.24 | 419.62 | -1.77% |
| Dow JONES (US) | 45,757.90 | 125.55 | -0.27% |
| FTSE 100 | 9,195.66 | 81.37 | -0.88% |
| HKSE | 26,438.51 | 8.05 | -0.03% |
| NASDAQ | 22,333.96 | 14.79 | -0.07% |
| Nikkei 225 | 44,821.03 | 81.24 | -0.18% |
| NZX 50 Index | 13,166.69 | 68.20 | -0.52% |
| S&P 500 | 6,606.76 | 8.52 | -0.13% |
| S&P/ASX 200 | 8,841.70 | 6.80 | -0.08% |
| SSE Composite Index | 3,859.56 | 2.30 | -0.06% |